Certain Botulinum Toxin Products and Processes for Manufacturing or Relating to Same; Notice of Request for Submissions on the Public Interest
The ITC is investigating certain botulinum toxin products for patent infringement, which could disrupt supply and increase costs for med-spas using these products.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Med-spas and aesthetics clinics using botulinum toxin products (e.g., Botox, Dysport, Xeomin) from manufacturers under investigation. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Public interest submissions are due by July 3, 2024. Businesses should assess their supply chain by this date.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The ITC issued a notice requesting public interest submissions regarding an investigation into certain botulinum toxin products and manufacturing processes. This could lead to import bans or restrictions on infringing products.
Who it affects
Med-spas and aesthetics clinics using botulinum toxin products (e.g., Botox, Dysport, Xeomin) from manufacturers under investigation.
What you must do
Monitor the investigation and identify alternative suppliers. Consider stockpiling or diversifying product lines to mitigate potential supply disruptions.
Deadline
Public interest submissions are due by July 3, 2024. Businesses should assess their supply chain by this date.
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
- Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
- Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
- Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication